ALKERMES | ALKS - Dochód Netto





Dochód Netto Zmiana Data
AbbVie USD 3.61B 2.92B 2026-06
Acadia Pharmaceuticals USD 31.5M 27.86M 2026-06
ALKERMES USD 501K 66.98M 2026-06
Amgen USD 2.38B 556M 2026-06
Biogen USD 97.5M 222M 2026-06
BioMarin Pharmaceutical USD 44.76M 60.76M 2026-06
Bristol-Myers Squibb USD 3.32B 640M 2026-06
Coherus Biosciences USD -37.64M 2.11M 2025-12
Eli Lilly USD 7.1B 301M 2026-06
Gilead Sciences USD -10.5B 12.52B 2026-06
Heron Therapeutics USD -2.95M 14.54M 2025-12
Ionis Pharmaceuticals USD -114.65M 21.65M 2026-06
J&J USD 5.53B 299M 2026-06
Malin Corporation EUR -1.1M 2.2M 2023-12
Merck USD -1.34B 2.9B 2026-06
Minerva Neurosciences USD 1.44M 21.07M 2024-12
Nektar Therapeutics USD -44.9M 8.82M 2026-03
Neurocrine Biosciences USD 144.4M 53.5M 2026-06
Otsuka Holdings JPY 117.26B 18.92B 2026-06
Ovoca Bio EUR 4.42M 5.19M 2025-12
Pfizer USD -248M 2.94B 2026-06
Regeneron Pharmaceuticals USD 1.3B 569.7M 2026-06
Vertex Pharmaceuticals USD 1.1B 68.4M 2026-06